By Colin KellaherIntegra LifeSciences Holdings has agreed to buy ear, nose and throat (ENT) technology company Acclarent from a unit of Johnson & Johnson for $275 million in cash. Integra on Wednesday said the deal, which expands its portfolio of ENT products and technologies, also includes an additional $5 million based on the achievement of certain regulatory milestones. Princeton, N.J., medical-technology company Integra said Acclarent generated about $110 million in revenue in 2022. Integra, which has forecast revenue of $1.54 billion to $1.55 billion for 2023, said it expects to complete the acquisition by the second quarter of 2024. Write to Colin Kellaher at colin.kellaher@wsj.com(END) Dow Jones Newswires12-13-23 0648ET

Source: Wall Street Journal December 13, 2023 11:53 UTC